Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 7 of 7 entries
Sorted by: Best Match Show Resources per page
Improved Personalised Neuroendocrine Tumours' Diagnosis Predictive Power by New Receptor Somatostatin Image Processing Quantification.

Journal of personalized medicine

Stolniceanu CR, Moscalu M, Azoicai D, Tamba B, Volovat C, Grierosu I, Ionescu T, Jalloul W, Ghizdovat V, Gherasim R, Volovat S, Wang F, Fu J, Moscalu R, Matovic M, Stefanescu C.
PMID: 34683183
J Pers Med. 2021 Oct 17;11(10). doi: 10.3390/jpm11101042.

Although neuroendocrine tumours (NETs) are intensively studied, their diagnosis and consequently personalised therapy management is still puzzling due to their tumoral heterogeneity. In their theragnosis algorithm, receptor somatostatin scintigraphy takes the central place, the diagnosis receptor somatostatin analogue (RSA)...

Cite
Stolniceanu CR, Moscalu M, Azoicai D, et al. Improved Personalised Neuroendocrine Tumours' Diagnosis Predictive Power by New Receptor Somatostatin Image Processing Quantification. J Pers Med. 2021;11(10)doi: 10.3390/jpm11101042.
Stolniceanu, C. R., Moscalu, M., Azoicai, D., Tamba, B., Volovat, C., Grierosu, I., Ionescu, T., Jalloul, W., Ghizdovat, V., Gherasim, R., Volovat, S., Wang, F., Fu, J., Moscalu, R., Matovic, M., & Stefanescu, C. (2021). Improved Personalised Neuroendocrine Tumours' Diagnosis Predictive Power by New Receptor Somatostatin Image Processing Quantification. Journal of personalized medicine, 11(10), . https://doi.org/10.3390/jpm11101042
Stolniceanu, Cati Raluca, et al. "Improved Personalised Neuroendocrine Tumours' Diagnosis Predictive Power by New Receptor Somatostatin Image Processing Quantification." Journal of personalized medicine vol. 11,10 (2021). doi: https://doi.org/10.3390/jpm11101042
Stolniceanu CR, Moscalu M, Azoicai D, Tamba B, Volovat C, Grierosu I, Ionescu T, Jalloul W, Ghizdovat V, Gherasim R, Volovat S, Wang F, Fu J, Moscalu R, Matovic M, Stefanescu C. Improved Personalised Neuroendocrine Tumours' Diagnosis Predictive Power by New Receptor Somatostatin Image Processing Quantification. J Pers Med. 2021 Oct 17;11(10). doi: 10.3390/jpm11101042. PMID: 34683183; PMCID: PMC8539645.
Copy Download .nbib Format: NLM
A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer.

Oncotarget

Volovat SR, Ciuleanu TE, Koralewski P, Olson JEG, Croitoru A, Koynov K, Stabile S, Cerea G, Osada A, Bobe I, Volovat C.
PMID: 32913555
Oncotarget. 2020 Aug 18;11(33):3105-3117. doi: 10.18632/oncotarget.27684. eCollection 2020 Aug 18.

NC-6004 is a nanoparticle developed using micellar technology that can improve release of cisplatin, a standard treatment for many cancer types, and achieve selective distribution to tumors. Here, in the Phase II portion of this study, the activity, safety,...

Cite
Volovat SR, Ciuleanu TE, Koralewski P, et al. A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer. Oncotarget. 2020;11(33):3105-3117doi: 10.18632/oncotarget.27684.
Volovat, S. R., Ciuleanu, T. E., Koralewski, P., Olson, J. E. G., Croitoru, A., Koynov, K., Stabile, S., Cerea, G., Osada, A., Bobe, I., & Volovat, C. (2020). A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer. Oncotarget, 11(33), 3105-3117. https://doi.org/10.18632/oncotarget.27684
Volovat, Simona Ruxandra, et al. "A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer." Oncotarget vol. 11,33 (2020): 3105-3117. doi: https://doi.org/10.18632/oncotarget.27684
Volovat SR, Ciuleanu TE, Koralewski P, Olson JEG, Croitoru A, Koynov K, Stabile S, Cerea G, Osada A, Bobe I, Volovat C. A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer. Oncotarget. 2020 Aug 18;11(33):3105-3117. doi: 10.18632/oncotarget.27684. eCollection 2020 Aug 18. PMID: 32913555; PMCID: PMC7443368.
Copy Download .nbib Format: NLM
Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy.

SpringerPlus

Volovat C, Bondarenko IM, Gladkov OA, Elsässer R, Buchner A, Bias P, Müller U.
PMID: 26155455
Springerplus. 2015 Jul 03;4:316. doi: 10.1186/s40064-015-1067-7. eCollection 2015.

PURPOSE: The aim of this study was to demonstrate lipegfilgrastim superiority versus placebo in adults with non-small cell lung cancer receiving myelosuppressive chemotherapy.METHODS: This phase III, double-blind study randomized chemotherapy-naive patients to receive cisplatin and etoposide with either lipegfilgrastim...

Cite
Volovat C, Bondarenko IM, Gladkov OA, et al. Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy. Springerplus. 2015;4:316doi: 10.1186/s40064-015-1067-7.
Volovat, C., Bondarenko, I. M., Gladkov, O. A., Elsässer, R., Buchner, A., Bias, P., & Müller, U. (2015). Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy. SpringerPlus, 4316. https://doi.org/10.1186/s40064-015-1067-7
Volovat, Constantin, et al. "Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy." SpringerPlus vol. 4 (2015): 316. doi: https://doi.org/10.1186/s40064-015-1067-7
Volovat C, Bondarenko IM, Gladkov OA, Elsässer R, Buchner A, Bias P, Müller U. Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy. Springerplus. 2015 Jul 03;4:316. doi: 10.1186/s40064-015-1067-7. eCollection 2015. PMID: 26155455; PMCID: PMC4489970.
Copy Download .nbib Format: NLM
MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review.

Frontiers in oncology

Volovat SR, Volovat C, Hordila I, Hordila DA, Mirestean CC, Miron OT, Lungulescu C, Scripcariu DV, Stolniceanu CR, Konsoulova-Kirova AA, Grigorescu C, Stefanescu C, Volovat CC, Augustin I.
PMID: 33330019
Front Oncol. 2020 Nov 20;10:526850. doi: 10.3389/fonc.2020.526850. eCollection 2020.

Noncoding RNAs (ncRNAs) include a diverse range of RNA species, including microRNAs (miRNAs) and long noncoding RNAs (lncRNAs). MiRNAs, ncRNAs of approximately 19-25 nucleotides in length, are involved in gene expression regulation either via degradation or silencing of the...

Cite
Volovat SR, Volovat C, Hordila I, et al. MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review. Front Oncol. 2020;10:526850doi: 10.3389/fonc.2020.526850.
Volovat, S. R., Volovat, C., Hordila, I., Hordila, D. A., Mirestean, C. C., Miron, O. T., Lungulescu, C., Scripcariu, D. V., Stolniceanu, C. R., Konsoulova-Kirova, A. A., Grigorescu, C., Stefanescu, C., Volovat, C. C., & Augustin, I. (2020). MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review. Frontiers in oncology, 10526850. https://doi.org/10.3389/fonc.2020.526850
Volovat, Simona Ruxandra, et al. "MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review." Frontiers in oncology vol. 10 (2020): 526850. doi: https://doi.org/10.3389/fonc.2020.526850
Volovat SR, Volovat C, Hordila I, Hordila DA, Mirestean CC, Miron OT, Lungulescu C, Scripcariu DV, Stolniceanu CR, Konsoulova-Kirova AA, Grigorescu C, Stefanescu C, Volovat CC, Augustin I. MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review. Front Oncol. 2020 Nov 20;10:526850. doi: 10.3389/fonc.2020.526850. eCollection 2020. PMID: 33330019; PMCID: PMC7716774.
Copy Download .nbib Format: NLM
A Comprehensive Review of the Use of Antioxidants and Natural Products in Cancer Patients Receiving Anticancer Therapy.

Anti-cancer agents in medicinal chemistry

Sur D, Gorzo A, Sabarimurugan S, Krishnan SM, Lungulescu CV, Volovat SR, Burz C.
PMID: 34488590
Anticancer Agents Med Chem. 2021 Aug 31; doi: 10.2174/1871520621666210901100827. Epub 2021 Aug 31.

Cancer is the leading cause of mortality and morbidity worldwide. The side effects of cancer treatment affect the quality of life. Cancer patients search for antioxidant dietary supplements and natural products during or after conventional cancer treatment for the...

Cite
Sur D, Gorzo A, Sabarimurugan S, et al. A Comprehensive Review of the Use of Antioxidants and Natural Products in Cancer Patients Receiving Anticancer Therapy. Anticancer Agents Med Chem. 2021;doi: 10.2174/1871520621666210901100827.
Sur, D., Gorzo, A., Sabarimurugan, S., Krishnan, S. M., Lungulescu, C. V., Volovat, S. R., & Burz, C. (2021). A Comprehensive Review of the Use of Antioxidants and Natural Products in Cancer Patients Receiving Anticancer Therapy. Anti-cancer agents in medicinal chemistry, . https://doi.org/10.2174/1871520621666210901100827
Sur, Daniel, et al. "A Comprehensive Review of the Use of Antioxidants and Natural Products in Cancer Patients Receiving Anticancer Therapy." Anti-cancer agents in medicinal chemistry vol. (2021). doi: https://doi.org/10.2174/1871520621666210901100827
Sur D, Gorzo A, Sabarimurugan S, Krishnan SM, Lungulescu CV, Volovat SR, Burz C. A Comprehensive Review of the Use of Antioxidants and Natural Products in Cancer Patients Receiving Anticancer Therapy. Anticancer Agents Med Chem. 2021 Aug 31; doi: 10.2174/1871520621666210901100827. Epub 2021 Aug 31. PMID: 34488590.
Copy Download .nbib Format: NLM
Nanomedicine to modulate immunotherapy in cutaneous melanoma (Review).

Experimental and therapeutic medicine

Volovat SR, Negru S, Stolniceanu CR, Volovat C, Lungulescu C, Scripcariu D, Cobzeanu BM, Stefanescu C, Grigorescu C, Augustin I, Lupascu Ursulescu C, Volovat CC.
PMID: 33815608
Exp Ther Med. 2021 May;21(5):535. doi: 10.3892/etm.2021.9967. Epub 2021 Mar 23.

Cancer immunotherapy has shifted the paradigm in cancer treatment in recent years. Immune checkpoint blockage (ICB), the active cancer vaccination and chimeric antigen receptor (CAR) for T-cell-based adoptive cell transfer represent the main developments, achieving a surprising increased survival...

Cite
Volovat SR, Negru S, Stolniceanu CR, et al. Nanomedicine to modulate immunotherapy in cutaneous melanoma (Review). Exp Ther Med. 2021;21(5):535doi: 10.3892/etm.2021.9967.
Volovat, S. R., Negru, S., Stolniceanu, C. R., Volovat, C., Lungulescu, C., Scripcariu, D., Cobzeanu, B. M., Stefanescu, C., Grigorescu, C., Augustin, I., Lupascu Ursulescu, C., & Volovat, C. C. (2021). Nanomedicine to modulate immunotherapy in cutaneous melanoma (Review). Experimental and therapeutic medicine, 21(5), 535. https://doi.org/10.3892/etm.2021.9967
Volovat, Simona Ruxandra, et al. "Nanomedicine to modulate immunotherapy in cutaneous melanoma (Review)." Experimental and therapeutic medicine vol. 21,5 (2021): 535. doi: https://doi.org/10.3892/etm.2021.9967
Volovat SR, Negru S, Stolniceanu CR, Volovat C, Lungulescu C, Scripcariu D, Cobzeanu BM, Stefanescu C, Grigorescu C, Augustin I, Lupascu Ursulescu C, Volovat CC. Nanomedicine to modulate immunotherapy in cutaneous melanoma (Review). Exp Ther Med. 2021 May;21(5):535. doi: 10.3892/etm.2021.9967. Epub 2021 Mar 23. PMID: 33815608; PMCID: PMC8014970.
Copy Download .nbib Format: NLM
Oncogenic mechanisms in renal insufficiency.

Clinical kidney journal

Volovat SR, Volovat C, Miron I, Kanbay M, Goldsmith D, Lungulescu C, Badarau SC, Covic A.
PMID: 33623673
Clin Kidney J. 2020 Oct 23;14(2):507-515. doi: 10.1093/ckj/sfaa122. eCollection 2021 Feb.

The prevalence of both cancer and end-stage renal disease is increasing. In addition, medical advances have meant increased survival rates for both diseases. Many chemotherapeutics are renally excreted, and conversely, renal insufficiency promotes a pro-neoplastic state, including genitourinary and...

Cite
Volovat SR, Volovat C, Miron I, et al. Oncogenic mechanisms in renal insufficiency. Clin Kidney J. 2020;14(2):507-515doi: 10.1093/ckj/sfaa122.
Volovat, S. R., Volovat, C., Miron, I., Kanbay, M., Goldsmith, D., Lungulescu, C., Badarau, S. C., & Covic, A. (2021). Oncogenic mechanisms in renal insufficiency. Clinical kidney journal, 14(2), 507-515. https://doi.org/10.1093/ckj/sfaa122
Volovat, Simona Ruxandra, et al. "Oncogenic mechanisms in renal insufficiency." Clinical kidney journal vol. 14,2 (2021): 507-515. doi: https://doi.org/10.1093/ckj/sfaa122
Volovat SR, Volovat C, Miron I, Kanbay M, Goldsmith D, Lungulescu C, Badarau SC, Covic A. Oncogenic mechanisms in renal insufficiency. Clin Kidney J. 2020 Oct 23;14(2):507-515. doi: 10.1093/ckj/sfaa122. eCollection 2021 Feb. PMID: 33623673; PMCID: PMC7886561.
Copy Download .nbib Format: NLM
Showing 1 to 7 of 7 entries